Correlation Between Sartorius Stedim and Virbac SA

Can any of the company-specific risk be diversified away by investing in both Sartorius Stedim and Virbac SA at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sartorius Stedim and Virbac SA into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Sartorius Stedim Biotech and Virbac SA, you can compare the effects of market volatilities on Sartorius Stedim and Virbac SA and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sartorius Stedim with a short position of Virbac SA. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sartorius Stedim and Virbac SA.

Diversification Opportunities for Sartorius Stedim and Virbac SA

0.22

Correlation Coefficient

Sartorius Stedim  Virbac SA

Modest diversification

The 3 months correlation between Sartorius and Virbac is 0.22. Overlapping area represents the amount of risk that can be diversified away by holding Sartorius Stedim Biotech and Virbac SA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Virbac SA and Sartorius Stedim is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sartorius Stedim Biotech are associated (or correlated) with Virbac SA. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Virbac SA has no effect on the direction of Sartorius Stedim i.e., Sartorius Stedim and Virbac SA go up and down completely randomly.

Pair Corralation between Sartorius Stedim and Virbac SA

Assuming the 90 days trading horizon Sartorius Stedim Biotech is expected to generate 1.41 times more return on investment than Virbac SA. However, Sartorius Stedim is 1.41 times more volatile than Virbac SA. It trades about 0.03 of its potential returns per unit of risk. Virbac SA is currently generating about -0.02 per unit of risk. If you would invest  17,375  in Sartorius Stedim Biotech on September 1, 2024 and sell it today you would earn a total of  660.00  from holding Sartorius Stedim Biotech or generate 3.8% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Sartorius Stedim Biotech  vs.  Virbac SA

Sartorius Stedim Biotech

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Sartorius Stedim Biotech are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak primary indicators, Sartorius Stedim may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Virbac SA

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Virbac SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Virbac SA is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Sartorius Stedim and Virbac SA

The main advantage of trading using opposite Sartorius Stedim and Virbac SA positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sartorius Stedim position performs unexpectedly, Virbac SA can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Virbac SA will offset losses from the drop in Virbac SA's long position.

The idea behind Sartorius Stedim Biotech and Virbac SA pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.